- Home
- SSTI vs QNCX Comparison
SSTI vs QNCX Comparison
Compare SSTI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTI
- QNCX
- Stock Information
- Founded
- SSTI 1996
- QNCX 2012
- Country
- SSTI United States
- QNCX United States
- Employees
- SSTI N/A
- QNCX N/A
- Industry
- SSTI Computer Software: Prepackaged Software
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSTI Technology
- QNCX Health Care
- Exchange
- SSTI Nasdaq
- QNCX Nasdaq
- Market Cap
- SSTI 102.1M
- QNCX 88.6M
- IPO Year
- SSTI 2017
- QNCX 2019
- Fundamental
- Price
- SSTI $8.45
- QNCX $1.70
- Analyst Decision
- SSTI Buy
- QNCX Strong Buy
- Analyst Count
- SSTI 7
- QNCX 4
- Target Price
- SSTI $20.29
- QNCX $7.75
- AVG Volume (30 Days)
- SSTI 115.1K
- QNCX 359.3K
- Earning Date
- SSTI 11-12-2025
- QNCX 11-12-2025
- Dividend Yield
- SSTI N/A
- QNCX N/A
- EPS Growth
- SSTI N/A
- QNCX N/A
- EPS
- SSTI N/A
- QNCX N/A
- Revenue
- SSTI $103,899,000.00
- QNCX N/A
- Revenue This Year
- SSTI $11.17
- QNCX N/A
- Revenue Next Year
- SSTI $9.39
- QNCX N/A
- P/E Ratio
- SSTI N/A
- QNCX N/A
- Revenue Growth
- SSTI 1.47
- QNCX N/A
- 52 Week Low
- SSTI $7.74
- QNCX $0.72
- 52 Week High
- SSTI $19.43
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- SSTI 30.46
- QNCX 51.06
- Support Level
- SSTI $7.73
- QNCX $1.44
- Resistance Level
- SSTI $8.38
- QNCX $1.84
- Average True Range (ATR)
- SSTI 0.54
- QNCX 0.12
- MACD
- SSTI -0.08
- QNCX -0.00
- Stochastic Oscillator
- SSTI 20.88
- QNCX 64.37
About SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.